We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
Keywords: Belarus; France; MDR TB; Mycobacterium tuberculosis; South Africa; TB; Tajikistan; United Kingdom; Uzbekistan; XDR TB; adolescents; antimicrobial resistance; bacteria; bedaquiline; children; multidrug resistance; multidrug-resistant tuberculosis; off-label use; pediatric; respiratory infections; treatment; tuberculosis.